In this randomized , double-blind , placebo-controlled , multicenter trial ( ClinicalTrials.gov NCT@ ) , patients experiencing @-@ migraine days during a @-week baseline were randomized to telcagepant @ mg , telcagepant @ mg , or placebo twice daily for @ weeks .